BM32

Unassigned

New Medicines

Hayfever, confirmed allergy to grass pollen extract with moderate to severe symptoms

Information

Vaccine
Biomay
Not Known

Development and Regulatory status

Phase II Clinical Trials
Phase II Clinical Trials
Unknown

Category

Grass pollen allergy vaccine based on recombinant peptide carrier proteins which are constructed from the immunogenic material.
Allergy to grass pollen is common and affects around 2 of every 10 people in the UK. A small minority of these pts suffer with severe symptoms of allergy [1].
Hayfever, confirmed allergy to grass pollen extract with moderate to severe symptoms
Subcutaneous injection